updated findings after 5-year follow-up for ruxolitinib in pv
Published 5 years ago • 139 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
1:32
response-2: 5-year follow-up of second-line ruxolitinib therapy for pv
-
1:23
response-2 5-year follow-up update: ruxolitinib vs bat in polycythemia vera without splenomegaly
-
1:09
significance of findings in response trial in polycythemia vera
-
4:52
treating pv with jak inhibition now and in the future
-
2:30
dr. harrison on 5-year follow-up data on ruxolitinib in patients with myelofibrosis
-
1:10
follow-up results for ruxolitinib in the second-line treatment of pv
-
2:09
majic update: promising results for ruxolitinib in pv and et
-
3:34
a response to ruxolitinib: update on 4-year trial follow-up
-
6:39
ruxolitinib patient selection in polycythemia vera
-
1:46
results for the follow-up of the response study
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
1:40
understanding the role of ruxolitinib in patients with polycythemia vera
-
6:07
available treatment options for patients with pv
-
5:10
ruxolitinib for relapsed/refractory or hydroxyurea-intolerant polycythemia vera patients
-
5:50
case 2: the response trial of ruxolitinib for pv
-
0:31
exploring the benefits of ruxolitinib in second-line polycythemia vera
-
4:43
the role of ruxolitinib in treating polycythemia vera
-
0:52
reveal study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea
-
1:58
significant developments in diagnosing pv